Changes in circulating level of IGF-I and IGF-binding protein-1 from the first to second trimester as predictors of preeclampsia

European Journal of Endocrinology

Volumn 158, Issue 1, 2008, Pages 101-105

  Vatten, Lars J ^a   Nilsen, Tom I L ^a   Juul, Anders ^b   Jeansson, Stig ^c   Jenum, Pål A ^d   Eskild, Anne ^e,f  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d VESTRE VIKEN HOSPITAL TRUST   (Norway)

^e NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^f AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN C;

ADULT; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; METABOLIC DISORDER; PLACENTA DISORDER; PREDICTION; PREECLAMPSIA; PREMATURITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SECOND TRIMESTER PREGNANCY;

EID: 38949106611     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-07-0386     Document Type: Article

References (18)

1. Roberts JM & Lain KY. Recent insights into the pathogenesis of pre-eclampsia. Placenta 2002 23 359-372.
2. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP & Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. Journal of Clinical Investigation 2003 111 649-658.
3. Chellakooty M, Vangsgaard K, Larsen T, Scheike T, Falck-Larsen J, Legarth J, Andersson AM, Main KM, Skakkebaek NE & Juul A. A longitudinal study of intrauterine growth and the placental growth hormone (GH)-insulin-like growth factor I axis in maternal circulation: association between placental GH and fetal growth. Journal of Clinical Endocrinology and Metabolism 2004 89 384-391.
4. Giudice LC, Martina NA, Crystal RA, Tazuke S & Druzin M. Insulin-like growth factor binding protein-1 at the maternal-fetal interface and insulin-like growth factor-I, insulin-like growth factor II, and insulin-like growth factor binding protein-1 in the circulation of women with severe preeclampsia. American Journal of Obstetrics and Gynecology 1997 176 751-758.
5. Grobman WA & Kazer RR. Serum insulin, insulin-like growth factor-I, and insulin-like growth factor binding protein-1 in women who develop preeclampsia. Obstetrics and Gynecology 2001 97 521-526.
6. de Groot CJ, O'Brien TJ & Taylor RN. Biochemical evidence of impaired trophoblast invasion of decidual stroma in women destined to have preeclampsia. American Journal of Obstetrics and Gynecology 1996 175 24-29.
7. Anim-Nyame N, Hills FA, Sooranna SR, Steer PJ & Johnsen MR. A longitudinal study of maternal plasma insulin-like growth factor bindng protein-1 concentrations during normal pregnancy and pregnancies complicated by preeclampsia. Human Reproduction 2000 15 2215-2219.
8. Hietala R, Pohja-Nylander P, Rutanen EM & Laatikainen T. Serum insulin-like growth factor binding protein-1 at 16 weeks and subsequent preeclampsia. Obstetrics and Gynecology 2000 95 185-189.
9. Jenum PA, Stray-Pedersen B, Melby KK, Kapperud G, Whitelaw A, Eskild A & Eng J. Incidence of Toxoplasma gondii infection in 35 940 pregnant women in Norway and pregnancy outcome for infected women. Journal of Clinical Microbiology 1998 36 2900-2906.
10. Chan JM, Stampfer MJ, Giovannuci E, Gann PH, Ma J, Wilkinson P, Hennekens CH & Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998 279 563-566.
11. Ning Y, Williams MA, Vadachkoria S, Muy-Rivera M, Frederick IO & Luthy DA. Maternal plasma concentrations of insulin-like growth factor-I and insulin-like growth factor-binding protein-1 in early pregnancy and subsequent risk of preeclampsia. Clinical Biochemistry 2004 37 968-973.
12. Lonberg U, Damm P, Andersson AM, Main KM, Chellakooty M, Lauenborg J, Skakkebaek NE & Juul A. Increase in maternal placental growth hormone during pregnancy and disappearance during parturition in normal and growth hormone-deficient pregnancies. American Journal of Obstetrics and Gynecology 2003 188 247-251.
13. Chellakooty M, Skibsted L, Skouby SO, Andersson AM, Petersen JH, Main KM, Skakkebaek NE & Juul A. Longitudinal study of serum placental GH in 455 normal pregnancies: correlation to gestational age, fetal gender, and weight. Journal of Clinical Endocrinology and Metabolism 2002 87 2734-2739.
14. Caufriez A, Frankenne P, Hennen G & Copinschi G. Regulation of maternal IGF-I by placental GH in normal and abnormal human pregnancies. American Journal of Physiology 1993 265 E572-E577.
15. Papadopoulou E, Sifakis S, Giahnakis E, Fragouli Y, Karkavitsas N, Koumantakis E & Kalmanti M. Increased human placental growth hormone at midtrimester pregnancies may be an index of intrauterine growth retardation related to preeclampsia. Growth Hormone and IGF Research 2006 16 290-296.
16. Vatten LJ & Skjærven R. Is preeclampsia more than one disease? British Journal of Obstetrics and Gynaecology 2004 111 298-302.
17. Irgens HU, Reisaeter L, Irgens LM & Lie RT. Long term mortality of mothers and fathers after pre-eclampsia: population-based cohort study. BMJ 2001 323 1213-1217.
18. Kalme T, Seppala M, Qiao Q, Koistinen R, Nissinen A, Harrela M, Loukovaara M, Leinonen P & Tuomilehto J. Sex-hormone-binding globulin and insulin-like growth factor binding protein-1 as indicators of metabolic syndrome, cardiovascular risk, and mortality in elderly men. Journal of Clinical Endocrinology and Metabolism 2005 90 1550-1556.